華檢醫療(01931.HK)與仁和藥業(000650.SZ)附屬戰略合作
華檢醫療(01931.HK)公佈,與仁和藥業(000650.SZ)間接全資附屬公司仁和國際達成重大戰略合作,於美國共同籌建全球首家非處方藥(OTC)垂直領域RWA交易所。
仁和國際與集團生態內附屬公司ETHK Inc簽署戰略合作協議,共同籌建並營運該專屬OTC RWA交易所。ETHK Inc將主要依託其合規資質與營運經驗,提供交易所所需的合規營運支持與服務。仁和藥業與公司旗下專業主體華檢數字簽署技術開發服務協議,華檢數字將提供交易所核心技術開發服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.